Diagnosticos da America S.A.BMFBOVESPA: DASA3

Diagnósticos da América: EBITDA up 14% and leverage down 20% as margin focus and restructuring drive improvements

· Issued by Diagnosticos da America S.A.

Operational efficiency and margin focus drove 14% EBITDA growth and 6% revenue increase year-over-year, while strict investment discipline and asset sales contributed to a 20% reduction in leverage. Ongoing restructuring and process optimization are expected to further improve margins and capital structure.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Diagnosticos da America S.A. on 6ix

Earlier from Diagnosticos da America

Later from Diagnosticos da America

All Diagnosticos da America news releases